RxDoctor Payments Data

Julie Gebhardt

Nurse Practitioner · Elk Grove Village, ILNPI 1003563214

Payments from drug & device makers

$7,868in general payments, 2019–2025

Across 210 payments — averaging $37.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$2K
  • Boehringer Ingelheim$1K
  • AstraZeneca$908
  • GSK$898
  • Mylan Specialty L.p.$390
  • Pulmonx Corporation$300
  • plus $2K from 24 others

What the payments were for

  • Consulting fees$6308%
  • Travel & lodging$320%
  • Food & beverage$7,16691%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,868 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$46,878
Medicare patients
322
Services billed
450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate250$3,235,211
EsbrietPirfenidone24$259,869
Trelegy ElliptaFluticasone/Umeclidin/Vilanter134$148,455
Pirfenidone36$34,446
Stiolto RespimatTiotropium Br/Olodaterol Hcl31$24,649
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$21,773
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$21,229
Breo ElliptaFluticasone/Vilanterol25$15,258
SymbicortBudesonide/Formoterol Fumarate14$4,907
Advair HfaFluticasone Propion/Salmeterol11$3,809
Incruse ElliptaUmeclidinium Bromide11$3,737
Albuterol Sulfate HfaAlbuterol Sulfate113$3,094
Ventolin HfaAlbuterol Sulfate32$2,106
Azithromycin81$814
Mycophenolate Mofetil11$753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat$1,404$3,259,861281 claims
Genentech USA, Inc.Esbriet$18$259,86924 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$898$189,223198 claims
AstraZenecaBreztri Aerosphere, Symbicort$908$26,13742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Elk Grove Village

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →